FGF Signaling Pathway in Neurodegeneration describes a key molecular or cellular mechanism implicated in neurodegenerative disease. This page provides a detailed overview of the pathway components, signaling cascades, and their relevance to conditions such as Alzheimer's disease, Parkinson's disease, and related disorders.
The fibroblast growth factor (FGF) signaling family comprises one of the most important cytokine systems in the central nervous system, playing critical roles in neuronal development, survival, and plasticity. The FGF family consists of 22 members in humans, divided into seven subfamilies based on sequence homology and receptor binding affinity[@ornitz2015]. These signaling molecules regulate fundamental processes including neurogenesis, synaptic formation, cognitive function, and response to neuronal injury. Emerging evidence demonstrates that FGF signaling dysfunction contributes significantly to the pathogenesis of Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative disorders[@echevarria2021].
```mermaid
graph TD
A["FGF Ligands"] --> B["FGFR Tyrosine Kinases"]
B --> C["RAS/MAPK Pathway"]
B --> D["PI3K/AKT Pathway"]
B --> E["PLCgamma Pathway"]
C --> F["Cell Proliferation"]
C --> G["Gene Expression"]
D --> H["Cell Survival"]
D --> I["mTOR Activation"]
E --> J["Calcium Signaling"]
E --> K["PKC Activation"]
FGF Signaling Pathway in Neurodegeneration describes a key molecular or cellular mechanism implicated in neurodegenerative disease. This page provides a detailed overview of the pathway components, signaling cascades, and their relevance to conditions such as Alzheimer's disease, Parkinson's disease, and related disorders.
The fibroblast growth factor (FGF) signaling family comprises one of the most important cytokine systems in the central nervous system, playing critical roles in neuronal development, survival, and plasticity. The FGF family consists of 22 members in humans, divided into seven subfamilies based on sequence homology and receptor binding affinity[@ornitz2015]. These signaling molecules regulate fundamental processes including neurogenesis, synaptic formation, cognitive function, and response to neuronal injury. Emerging evidence demonstrates that FGF signaling dysfunction contributes significantly to the pathogenesis of Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative disorders[@echevarria2021].
The fibroblast growth factor family includes both canonical FGFs (FGF1-14, FGF16-23) and non-canonical FGFs (FGF19, FGF21, FGF23). In the central nervous system, several FGFs are particularly important for neuronal function[@reuss2020]:
FGF1 (aFGF) is expressed throughout the brain and binds to all FGFR isoforms with low affinity. It promotes neuronal survival and proliferation, and its levels are altered in neurodegenerative disease brain tissue.
FGF2 (bFGF) is one of the most studied neurotrophic factors in the brain. It promotes neurogenesis, neuronal differentiation, and synaptic plasticity. FGF2 is upregulated in response to neuronal injury and has neuroprotective properties against various toxic insults[@zhao2019].
FGF9 is expressed in astrocytes and promotes glial proliferation and neurite outgrowth. It plays important roles in brain development and is implicated in neuroinflammatory responses.
FGF18 is expressed in the hippocampus and cortex, where it promotes neurogenesis and synaptic plasticity. Reduced FGF18 expression has been linked to cognitive decline in aging and AD[@kimura2021].
FGF21 is a metabolic regulator with increasing evidence for neuroprotective effects. It crosses the blood-brain barrier and may have therapeutic potential in neurodegenerative diseases.
Fibroblast growth factor receptors (FGFR1-4) are transmembrane tyrosine kinase receptors that mediate FGF signaling. FGFR1 and FGFR2 are widely expressed in the brain, with particularly high levels in the hippocampus and cortex[@fordpassanen2020]:
FGFR1 is highly expressed in neural stem cells and promotes neurogenesis. It plays essential roles in hippocampal development and function. FGFR1 signaling is downregulated in AD brain, contributing to impaired neurogenesis.
FGFR2 is expressed in neural progenitor cells and promotes neuronal differentiation. It is important for cortical development and cognitive function.
FGFR3 is expressed in oligodendrocyte progenitor cells and promotes oligodendrocyte differentiation and myelination. FGFR3 dysfunction contributes to demyelination in neurodegenerative diseases.
FGFR4 has more restricted expression in the brain but is involved in dopaminergic neuron survival. Mutations in FGFR4 have been linked to PD susceptibility.
Alzheimer's disease is characterized by progressive cognitive decline, and FGF signaling plays crucial roles in hippocampal neurogenesis, which is impaired in AD[@martens2022]. The hippocampus contains neural stem cells in the subgranular zone of the dentate gyrus that continue to generate new neurons throughout life. FGF2 signaling is essential for maintaining these neural stem cells and promoting their differentiation into functional neurons.
In AD brain tissue, both FGF2 and FGFR1 expression are reduced in the hippocampus. This downregulation correlates with decreased neurogenesis and cognitive impairment. Amyloid-beta (Aβ) peptides, the hallmark of AD, directly suppress FGF signaling through multiple mechanisms. Aβ reduces FGF2 expression in neural progenitor cells and impairs FGFR1 signaling downstream pathways, including MAPK and PI3K/AKT[@chen2021].
FGF signaling is critical for synaptic formation and plasticity. FGF2 promotes synaptic protein expression and enhances long-term potentiation (LTP) in the hippocampus. In AD, impaired FGF signaling contributes to synaptic dysfunction and memory deficits.
The NMDA receptor signaling and FGF signaling pathways intersect at multiple points. FGF2 enhances NMDA receptor expression and function, and this cross-talk is disrupted in AD. Additionally, FGF signaling modulates AMPA receptor trafficking, which is important for synaptic plasticity[@nakamachi2020].
FGF signaling interacts with both amyloid-beta and tau pathology in AD. Aβ accumulation suppresses FGF signaling through multiple mechanisms, including reduced receptor expression and impaired downstream signaling. Conversely, FGF signaling can modulate Aβ production and clearance.
FGF2 and FGF18 both affect amyloid precursor protein (APP) processing. FGF signaling through FGFR1 can reduce BACE1 expression, decreasing Aβ production. Additionally, FGF signaling promotes the activity of the autophagy-lysosome pathway, enhancing Aβ clearance[@liu2022].
Tau pathology is also influenced by FGF signaling. FGF signaling through the MAPK pathway can affect tau phosphorylation. GSK-3β, a key kinase in tau hyperphosphorylation, is regulated by PI3K/AKT signaling downstream of FGFRs. Dysregulated FGF signaling may contribute to tau pathology progression.
Parkinson's disease is characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta. FGF signaling is essential for the survival and maintenance of these neurons. Both FGF2 and FGF8 promote dopaminergic neuron differentiation during development and protect these neurons from various toxic insults[@timm].
In PD brain tissue, FGF2 expression is altered in the substantia nigra. The neuroprotective effects of FGF2 against 6-hydroxydopamine (6-OHDA) and MPTP toxicity have been demonstrated in multiple model systems. FGF2 protects dopaminergic neurons through PI3K/AKT signaling and reduces caspase activation.
The protein alpha-synuclein, which forms Lewy bodies in PD, interacts with FGF signaling pathways. Wild-type alpha-synuclein can enhance FGFR signaling, while mutant forms impair this signaling. This interaction may contribute to the vulnerability of dopaminergic neurons.
FGF signaling may also affect alpha-synuclein aggregation and clearance. FGF signaling through mTOR can modulate autophagy, which is important for alpha-synuclein clearance. Impaired FGF signaling may contribute to alpha-synuclein accumulation[@schapansky2020].
Neuroinflammation plays a significant role in PD pathogenesis. FGF signaling modulates microglial activation and inflammatory responses. FGF2 has anti-inflammatory effects on microglia, reducing the production of pro-inflammatory cytokines.
However, chronic inflammation can suppress FGF signaling, creating a feed-forward loop that exacerbates neurodegeneration. The balance between pro-inflammatory and anti-inflammatory effects of FGF signaling is critical for maintaining neuronal health.
FGF signaling is dysregulated in ALS, a progressive neurodegenerative disease affecting motor neurons. Both FGF2 and FGFR1 expression are altered in ALS spinal cord tissue. The neurotrophic effects of FGF signaling may have therapeutic potential for motor neuron protection[@boillee2019].
FGF9 is expressed in astrocytes and promotes astrocyte proliferation in response to injury. In ALS, reactive astrocytes release FGF9, which may modulate disease progression. The role of FGF signaling in astrocyte-mediated neuroprotection is an area of active investigation.
FGF signaling is implicated in Huntington's disease (HD), an autosomal dominant neurodegenerative disorder caused by CAG repeat expansion in the HTT gene. FGF signaling promotes striatal neuron survival, and this protection is impaired in HD.
The mutant huntingtin protein interferes with FGF signaling through multiple mechanisms. It reduces FGFR1 expression and impairs downstream signaling. Additionally, FGF2 levels are reduced in HD brain tissue, contributing to neuronal vulnerability[@goto2021].
FGF signaling regulates oligodendrocyte progenitor cell (OPC) proliferation and differentiation. FGFR3 signaling is particularly important for myelination. In multiple sclerosis, remyelination failure may be related to dysregulated FGF signaling.
Paradoxically, FGF signaling can both promote and inhibit remyelination depending on the context. While FGF2 promotes OPC proliferation, excessive FGF2 signaling can inhibit oligodendrocyte differentiation, impairing remyelination. The timing and context of FGF modulation are critical for therapeutic applications[@furusho2020].
Recombinant FGF2 protein has been tested in animal models of neurodegenerative diseases. Intracerebral or intravenous FGF2 administration protects against various neurotoxic insults. However, the short half-life and limited blood-brain barrier penetration of FGF2 have limited clinical applications.
Small molecule FGFR agonists are being developed to overcome these limitations. These compounds activate FGFR signaling and may have neuroprotective effects. The challenge is achieving sufficient brain penetration while maintaining specificity[@wu2021].
In some contexts, FGF signaling may be excessive or dysregulated. FGFR antagonists may be beneficial in these cases, particularly for modulating inflammatory responses. However, chronic FGFR inhibition may have adverse effects on neuronal function.
Gene therapy to deliver FGF genes or enhance FGF signaling is being explored. AAV vectors encoding FGF2 have been tested in animal models and show neuroprotective effects. This approach may provide sustained delivery of neurotrophic factors[@bishop2020].
FGF signaling works synergistically with other neurotrophic pathways. Combinations of FGF with BDNF, GDNF, or other growth factors may provide enhanced neuroprotection. These combination approaches are being investigated in preclinical models.
FGF signaling interacts with multiple other pathological pathways in neurodegeneration:
The RAS/MAPK pathway is the canonical signaling cascade downstream of FGFR activation. Upon FGF binding, FGFR dimerization and autophosphorylation recruits adaptor proteins that activate RAS. RAS activates RAF, which activates MEK, which activates ERK[@takahashi2021].
The RAS/MAPK pathway regulates gene expression through ERK-mediated phosphorylation of transcription factors. This pathway promotes cell proliferation, differentiation, and survival. In neurons, MAPK signaling is important for synaptic plasticity and memory formation.
The PI3K/AKT pathway is another major signaling cascade downstream of FGFR. PI3K generates PIP3, which activates AKT. AKT phosphorylates multiple targets that promote cell survival, including GSK-3β and BAD[@read2019].
In neurons, PI3K/AKT signaling is particularly important for protecting against apoptotic cell death. This pathway is impaired in multiple neurodegenerative diseases, and enhancing PI3K/AKT signaling may have therapeutic benefits.
FGFR activation also stimulates phospholipase C gamma (PLCγ), which generates DAG and IP3. These second messengers activate protein kinase C (PKC) and increase intracellular calcium. This pathway modulates synaptic transmission and plasticity[@huang2022].
Aging is associated with reduced FGF signaling in the brain. FGF2 expression declines with age in the hippocampus and cortex. This decline correlates with reduced neurogenesis and impaired cognitive function.
The age-related reduction in FGF signaling may contribute to increased susceptibility to neurodegenerative diseases. Strategies to maintain FGF signaling during aging may help preserve cognitive function and reduce neurodegeneration risk.
Caloric restriction, which extends lifespan and improves cognitive function, enhances FGF21 signaling. FGF21 expression is increased in response to fasting and metabolic stress. The neuroprotective effects of caloric restriction may be partly mediated through FGF21[@lange2020].
Peripheral FGF levels may serve as biomarkers for neurodegenerative diseases. FGF2 levels in blood are altered in AD and PD patients. However, the relationship between peripheral and central FGF signaling is complex.
Cerebrospinal fluid FGF levels may more directly reflect brain FGF signaling. Reduced CSF FGF2 has been reported in AD patients. These biomarkers may aid in diagnosis and disease monitoring.
Polymorphisms in FGF genes may influence susceptibility to neurodegenerative diseases. FGF2 and FGFR1 variants have been associated with AD risk in genome-wide association studies. These genetic variants may affect FGF signaling efficiency[@sato2021].
FGF gene expression is regulated through epigenetic mechanisms including DNA methylation and histone modification. Altered epigenetic regulation of FGF genes has been reported in neurodegenerative diseases.
Sex differences in FGF signaling may contribute to the differential susceptibility to neurodegenerative diseases. Women show higher baseline FGF2 levels in certain brain regions, which may relate to the protective effects of estrogen. Estrogen can enhance FGF signaling, providing a potential mechanism for sex differences in disease risk[@suzuki2021].
FGF signaling is a critical neurotrophic system that promotes neuronal survival, neurogenesis, and synaptic plasticity. Dysregulation of FGF signaling contributes to the pathogenesis of multiple neurodegenerative diseases, including AD and PD. Understanding the mechanisms of FGF signaling dysfunction offers opportunities for therapeutic intervention. Targeting FGF signaling with small molecules, gene therapy, or combination approaches may provide neuroprotection in these devastating diseases.
FGF signaling plays important roles in response to ischemic stroke and brain injury. Following cerebral ischemia, FGF2 expression is upregulated in the brain, particularly in astrocytes surrounding the infarct zone[@kawaguchi2020]. This upregulation represents an endogenous neuroprotective response that promotes neuronal survival and tissue repair.
FGF2 protects neurons from ischemic injury through multiple mechanisms. It promotes angiogenesis, the formation of new blood vessels, which is critical for restoring blood supply to ischemic tissue. FGF2 also enhances astrocyte reactivity and the formation of glial scars, which help isolate damaged areas but may also inhibit regeneration[@sun2021].
The timing of FGF signaling is critical for its effects. Early FGF signaling promotes cell survival, while later phases may contribute to adverse remodeling. Understanding these temporal dynamics is important for developing effective therapeutic approaches.
Exogenous FGF2 administration has been tested in animal models of stroke. Both pre- and post-ischemic administration reduces infarct volume and improves functional outcomes. However, clinical trials have shown limited efficacy, likely due to challenges in delivery and timing[@jiang2019].
Traumatic brain injury (TBI) triggers complex responses involving FGF signaling. Immediately after TBI, FGF2 is released from damaged cells and activates repair mechanisms. The extent and timing of FGF signaling influences outcomes following brain injury[@bye2020].
Following TBI, FGF2 expression increases in astrocytes and microglia within hours. This early response promotes tissue repair and neuroprotection. However, excessive or prolonged FGF signaling may contribute to adverse outcomes including post-traumatic epileptogenesis.
In the chronic phase after TBI, FGF signaling continues to influence neural plasticity and recovery. Enhancing FGF signaling may improve functional outcomes by promoting neurogenesis and synaptic plasticity in surviving tissue.
While this review focuses on neurodegenerative diseases, FGF signaling is equally important in neurodevelopment. Dysregulated FGF signaling during development contributes to various neurodevelopmental disorders including autism spectrum disorders and schizophrenia[@nakamachi2021].
Altered FGF signaling has been implicated in schizophrenia. Both FGF2 and FGFR1 expression are dysregulated in postmortem brain tissue from schizophrenia patients. These alterations may contribute to the neurodevelopmental abnormalities seen in this disorder.
FGF signaling genes are mutated in some cases of autism spectrum disorders. FGFR mutations cause syndromic forms of autism including Apert syndrome. These findings highlight the importance of FGF signaling for normal brain development.
Diabetes mellitus increases risk for neurodegenerative diseases including AD and PD. FGF signaling may mediate some of these relationships. FGF21 improves insulin sensitivity and glucose metabolism, and these effects may extend to neuroprotection[@kuroda2020].
Metabolic syndrome, characterized by obesity, hypertension, and dyslipidemia, is a risk factor for neurodegeneration. FGF21 and FGF19 signaling may help address metabolic dysfunction while providing neuroprotective effects.
Glaucoma, a progressive optic neuropathy, involves retinal ganglion cell death. FGF signaling promotes retinal ganglion cell survival and may have therapeutic potential in glaucoma[@lambert2021]. FGF2 and FGFR expression in the retina make these proteins attractive targets.
Developing FGFR isoform-selective agonists and antagonists is a major research priority. Each FGFR isoform has distinct expression patterns and functions. Selective modulation may provide benefits while minimizing side effects[@tanda2022].
The blood-brain barrier limits delivery of large molecules like FGF proteins to the brain. Small molecule FGFR modulators that cross the BBB are needed. Current efforts focus on identifying brain-penetrant compounds.
Combining FGF signaling with stem cell therapies may enhance regeneration. FGF promotes stem cell survival and differentiation. This combination approach may provide enhanced benefits for neurodegenerative diseases[@ourednik2020].
Identifying biomarkers that predict response to FGF-targeted therapies will enable personalized treatment. Peripheral FGF levels or genetic variants may help select patients most likely to benefit.